Curasight (CURAS) Q4 2025 earnings summary

Executive summary

• Advanced uPAR-targeted theranostic solutions for aggressive solid tumors, leveraging a pipeline-in-a-drug approach for diagnosis and treatment.

• Achieved significant clinical and financial progress in Q4 2025, including first patient dosing in Phase 1 UTREAT® glioblastoma trial and momentum in uTRACE® Phase 2 prostate cancer trial.

• Expanded patent protection and secured new financing to support ongoing R&D and clinical activities.

Financial highlights

• FY 2025 gross loss was kDKK -49,676 (FY 2024: kDKK -32,731); operating loss was kDKK -55,592 (kDKK -40,367); loss for the year was kDKK -53,230 (kDKK -36,836).

• Cash in hand at year-end was kDKK 35,912 (kDKK 10,011 in 2024); total assets at year-end were kDKK 50,055 (kDKK 23,688).

• Q4 2025 gross loss: kDKK -14,577; operating loss: kDKK -16,203; loss for the period: kDKK -15,311.

• Q4 cash flow: kDKK 20,012; cash flow from operating activities Q4: kDKK -10,328.

Key financial ratios and metrics

• Equity ratio improved to 37.1% from 32.6% year-over-year.

• Earnings per share for FY 2025 was DKK -1.1, compared to DKK -1.74 last year.